Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Leukaemia: Medical Treatments

Department of Health and Social Care written question – answered on 23rd April 2018.

Alert me about debates like this

Photo of Mark Tami Mark Tami Opposition Pairing Whip (Commons)

To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the adequacy of the availability of treatment options for patients with relapsed acute lymphoblastic leukaemia in the (a) UK and (b) EU countries.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

No such assessment has been made.

There is a well-established framework for enabling access to cost effective new cancer medicines in England. All new licensed cancer medicines are referred to the National Institute for Health and Care Excellence (NICE) for inclusion within the Technology Appraisal Programme, this referral is irrespective of the clinical indication concerned. Where cancer medicines are approved by NICE for use in England, NHS England makes these available immediately. NICE now also has the ability to refer licensed medicines demonstrating promising, but not yet certain, benefits for inclusion within the Cancer Drugs Fund.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.